Nautilus Biotechnology Reports Results for Quarter Ended June 30, 2026

What Happened
Nautilus Biotechnology, Inc. (NAUT) filed a Form 8-K on July 28, 2026 to disclose that it issued a press release reporting its financial results for the quarter ended June 30, 2026. The press release is furnished as Exhibit 99.1 to the 8-K. The filing is signed by CEO Sujal Patel.

Key Details

• Filed Form 8-K on July 28, 2026 under Item 2.02 (Results of Operations and Financial Condition).
• Press release reporting quarterly results is attached as Exhibit 99.1.
• Covered period: quarter ended June 30, 2026.
• Report signed and filed on the company’s behalf by Sujal Patel, Chief Executive Officer.

Why It Matters
This 8-K notifies investors that Nautilus has publicly reported its latest quarterly financial results; the filing itself furnishes the press release but does not restate the financials in full. Retail investors should review the attached press release (Exhibit 99.1) and any subsequent SEC filings for the specific revenue, earnings, cash position, and management commentary to assess near-term financial performance and guidance.